Gyre Therapeutics

Historical price data

Gyre Therapeutics is a San Diego-based biotech focused on developing treatments for organ fibrosis, with a core mission to address the high unmet need in chronic liver and metabolic diseases. Its key achievement is the advancement of Hydronidone, which has secured Breakthrough Therapy designation in China for Hepatitis B-induced liver fibrosis and is now in a pivotal Phase 3 trial, while a Phase 2b study in MASH is planned for the U.S. The company's strategy is bifurcated: driving its lead candidate in major Western markets while leveraging its controlling interest in Beijing Continent to develop and commercialize a broader portfolio of fibrosis therapies across multiple indications in China and beyond.

Platform centered on small molecule inhibitors of fibrotic pathways, primarily TGF-β, with lead asset Hydronidone being a hepatic-targeted analog of pirfenidone. Expanding via acquisition into targeted protein degradation.

Gyre faces intense competition in MASH from approved therapies (e.g., resmetirom) and a crowded pipeline of late-stage candidates. Its differentiation lies in Hydronidone's targeted anti-fibrotic mechanism and de-risked clinical data. In China for Hepatitis B fibrosis, it appears to be a first-mover. The Cullgen acquisition places it in the competitive but innovative TPD field.